---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-006912"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2024-05-24T23:59:59+00:00"
generated_at: "2026-06-01T08:51:58.286677+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dermata Therapeutics regains Nasdaq compliance with publicly held shares rule

## Summary
- Received Nasdaq deficiency notice on May 20, 2024 for failing Rule 5550(a)(4) requiring at least 500,000 publicly held shares.
- Provided additional information and as of May 24, 2024, the Company has regained compliance and the matter is closed.
- No further action required; common stock (DRMA) and warrants (DRMAW) remain listed on Nasdaq.

## SEC filing metadata
- accession: 0001654954-24-006912
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2024-05-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000165495424006912/0001654954-24-006912-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000165495424006912/drma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-006912
- JSON: https://secwatch.observer/filing/0001654954-24-006912.json
- Plain text: https://secwatch.observer/filing/0001654954-24-006912.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.